Beeline Holdings sells $1.2 million in stock, totals $14.5 million since March
PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ: GH), a leader in precision oncology with a market capitalization of $4.8 billion and impressive revenue growth of 28.2% over the last twelve months, has announced significant enhancements to its Guardant360® Liquid test, which now includes advanced biomarker identification and cancer subtyping features. These improvements are aimed at aiding oncologists in determining the most effective treatment plans for patients. According to InvestingPro data, the company maintains a strong liquidity position with current assets exceeding short-term obligations by over 4 times, providing financial flexibility to support its innovative developments.
The new features are made possible by the Guardant360® smart liquid biopsy platform’s multiomic profiling capabilities, along with its AI learning engine, which refines predictions by analyzing vast patient data sets. The test’s groundbreaking applications include confirming the absence of actionable mutations in lung and colorectal cancers, identifying the origin of cancers with unknown primary sites, and classifying breast and lung cancer subtypes with high precision. The company’s commitment to innovation is reflected in its robust gross profit margin of 61.3%, though InvestingPro analysis indicates analysts don’t expect profitability this year.
Additionally, the Guardant360 Liquid test can now detect human papillomavirus (HPV) and Epstein-Barr virus (EBV), inform Homologous Recombination Deficiency (HRD) status for the use of specific therapies, and utilize Human Leukocyte Antigen (HLA) genotyping as a biomarker for therapy selection and clinical trial identification.
Helmy Eltoukhy, Guardant Health chairman and co-CEO, stated, "For the first time ever, we’re able to reveal vital details about a tumor – including its fundamental phenotype and biological behavior – from just a blood sample." This innovation provides healthcare providers with critical insights for smarter treatment decisions, especially when tumor tissue is inaccessible for analysis.
Traditionally, comprehensive biomarker testing through immunohistochemistry using tumor tissue has been the standard in oncology. The Guardant360 Liquid test now offers a blood-based alternative for accessing molecular profiling information, which is expected to be available within seven days of testing.
Guardant Health’s liquid biopsy tests have undergone clinical validation in over 1,000 publications and research abstracts. The company is dedicated to transforming patient care and accelerating new cancer therapies with its advanced blood and tissue tests, real-world data, and AI analytics.
This news is based on a press release statement and reflects the company’s expansion of its testing capabilities aimed at improving patient outcomes in the field of oncology. With analyst price targets ranging from $47 to $70 and eight analysts recently revising earnings estimates upward, the company’s strategic direction appears promising. For deeper insights into Guardant Health’s financial health and growth prospects, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports, which are available for over 1,400 US stocks.
In other recent news, Guardant Health reported a strong financial performance for the first quarter of 2025, with earnings per share of -$0.49 surpassing the forecasted -$0.75 and revenue reaching $203.5 million, exceeding the expected $190.01 million. This represents a 21% increase in revenue compared to the previous year. The company has also raised its full-year revenue guidance to a range of $880-$890 million. Scotiabank and Canaccord Genuity have responded positively to these results, with Scotiabank raising its price target to $57 and maintaining a Sector Outperform rating, while Canaccord increased its target to $65 and upheld a Buy rating.
Guardant Health has introduced new products, including the Guardant360 Tissue test and the Guardant Hereditary Cancer test. The Guardant360 Tissue test complements the existing multiomic profiling capabilities, while the hereditary cancer test aids in identifying genetic variants linked to increased cancer risk. Additionally, the company has expanded its oncology testing with a complete suite of immunohistochemistry (IHC) testing for key biomarkers in solid tumors.
The company’s Shield test, which is part of its screening portfolio, has received Advanced Diagnostic Laboratory Test (ADLT) status, leading to an increase in Medicare pricing. Guardant Health plans to reinvest some of its financial gains into commercial infrastructure, aiming for cash flow breakeven by 2028. The company’s continuous improvements in product offerings and strategic partnerships, such as a collaboration with Pfizer, are expected to drive future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.